NCT05364840View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

58

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

October 18, 2022

Study Completion Date

November 4, 2022

Conditions

COVID-19

Interventions

DRUG

STI-1558

Orally available protease inhibitor capsule

DRUG

Placebo

Placebo product capsule

Trial Locations (1)

2031

Scientia Clinical Research Ltd, Randwick

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY